Skip to main content
Clinical Trials/NCT01351766
NCT01351766
Completed
Phase 3

Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation

University of Maryland, College Park1 site in 1 country39 target enrollmentApril 2010

Overview

Phase
Phase 3
Intervention
Transdermal Nicotine Patch
Conditions
Smoking
Sponsor
University of Maryland, College Park
Enrollment
39
Locations
1
Primary Endpoint
Number of Participants Smoking-Abstinent for 7 Days, 12 Weeks Post Quit Date
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The primary purpose of this study is to develop a specialized behavioral activation treatment for smoking in youths ages 18-21 with elevated depressive symptoms. In the first phase we utilize focus groups and pilot testing with 15 youths to develop the behavioral activation smoking treatment for youth. In Phase II, we will conduct an open-label trial of the new treatment that will include 8 weeks of transdermal nicotine patch, which will begin at the time of quitting smoking. Participants will be followed over 26 weeks post-quit date. A subset of participants will also undergo an fMRI session to examine reward sensitivity.

Detailed Description

1. 18-21 years of age, 2. a regular smoker for at least 6 months 3. currently smoking an average of at least 5 cigarettes per day 4. want to quit smoking 5. report current elevated depressive symptoms

Registry
clinicaltrials.gov
Start Date
April 2010
End Date
May 2013
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Laura MacPherson

Study Principal Investigator

University of Maryland, College Park

Eligibility Criteria

Inclusion Criteria

  • between 18 and 21 years of age
  • a regular smoker for at least 6 months
  • currently smoking an average of at least 5 cigarettes per day
  • want to quit smoking
  • report current elevated depressive symptoms

Exclusion Criteria

  • current Axis I disorder
  • psychoactive substance dependence (excluding nicotine dependence) within the past 6 months
  • current use of psychotropic medication or participation in any form of psychotherapy
  • a history of significant medical condition (e.g., cardiovascular , neurological, gastrointestinal), pregnancy and/or breast feeding, or other systemic illness
  • limited mental competency \[Mini Mental State Examination score \< 23\] and/or the inability to give informed, voluntary, written consent to participate
  • current use of any pharmacotherapy for smoking cessation not provided by the researchers during the quit attempt
  • Additional Exclusion criteria only for the fMRI portion:
  • cerebrovascular disease
  • high blood pressure
  • use of psychotropic medications in 3 weeks prior to participation in fMRI protocol

Arms & Interventions

Behavioral Activation for Smoking

Eight 60-minute group sessions over an eight-week period. Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue after treatment sessions have ended. Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.

Intervention: Transdermal Nicotine Patch

Outcomes

Primary Outcomes

Number of Participants Smoking-Abstinent for 7 Days, 12 Weeks Post Quit Date

Time Frame: 12 weeks post quit date

7 days of smoking abstinence confirmed via expired carbon monoxide at 12 weeks

Study Sites (1)

Loading locations...

Similar Trials